Nicole Kucine, M.D.
My clinical interests include working with children with various blood disorders, such as sickle cell anemia, bleeding and blood clotting disorders, and different kinds of leukemia. I find it a privilege to be able to help families deal with their children's complex medical issues. By combining excellent, compassionate medical care with research aimed at improving outcomes and preventing disease-associated complications, I believe that we can make a difference for children with cancer and blood disorders.
After completing her Bachelor of Arts (BA) at Wellesley College, Dr. Nicole Kucine relocated to New York City where she received her medical degree (MD) from , State University of New York Health Science Center at Brooklyn (now the State University of New York-Downstate Medical Center). She completed her residency in Pediatrics at Robert Wood Johnson University Hospital in New Jersey in 2006 and served as Chief Resident from 2006-2007.
After residency, Dr. Kucine completed a fellowship in Pediatric Hematology/Oncology at the combined program of New York Hospital-Cornell University Medical College and the Memorial Sloan-Kettering Cancer Center (MSKCC). At MSKCC, she served as Special Fellow, looking at new therapeutic agents for high-risk acute lymphoblastic leukemia (ALL.)
At Weill Cornell, Dr. Kucine continues her research looking at new therapies for high-risk ALL. She is also interested in studying blood clotting in children, and anemia, such as anemia of chronic disease, nutritional anemias, and Sickle Cell Anemia. She looks forward to helping patients with a variety of hematologic medical concerns, including hematologic cancers.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA [PPO]
- AETNA [HMO]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP)
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Freedom]
- Oxford Health Plans [Liberty]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care [Medicare]
- United Health Care
- Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL. Efficacy of the JAK2 inhibitor INC16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010 Feb 12, PMID: 20154217
- Lluis Espinosa, Severine Cathelin,Teresa D'Altri, Thomas Trimarchi, Alexander Statnikov, Jordi Guiu, Veronica Rodilla, Julia Ingle´ s-Esteve, Josep Nomdedeu, Beatriz Bellosillo, Carles Besses, Omar Abdel-Wahab, Nicole Kucine, Shao-Cong Sun, Guangchan Song, Charles C. Mullighan, Ross L. Levine, Klaus Rajewsky, Iannis Aifantis, and Anna Bigas. The Notch/Hes1 Pathway Sustains NF-kB Activation through CYLD Repression in T Cell Leukemia. Cancer Cell 2010 September 14, PMID: 20832754
- Pediatric Hematology-Oncology
- Thrombotic Disorder
- Sickle Cell Anemia
- White Blood Cell Disorder
- Pediatric Hematology-Oncology
- B.A., Wellesley College, 1999
- M.D., State University of New York Health Science Center at Brooklyn, 2003